| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CRAM; DPYSL5; DRP5; Ulip6;;DRP 5 |
| WB Predicted band size | 61 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human DRP 5 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于CRMP5抗体的3篇参考文献的简要总结：
1. **"CRMP5 autoantibodies in paraneoplastic neurological syndrome"**
- **作者**：Vernino S, et al.
- **摘要**：研究探讨了CRMP5抗体在副肿瘤性神经综合征中的临床意义，发现其与肺癌(尤其是小细胞肺癌)相关，常见表现为周围神经病变、小脑共济失调及视网膜病变，提示抗体可能通过靶向神经元细胞骨架蛋白引发自身免疫反应。
2. **"Clinical analysis of anti-CRMP5 antibody-associated paraneoplastic neurological disorders"**
- **作者**：Yu Z, et al.
- **摘要**：通过回顾性病例分析，总结了CRMP5抗体阳性患者的临床特征，包括肌阵挛、舞蹈症及自主神经功能障碍，强调联合肿瘤筛查(如胸部CT)的重要性，并观察到免疫治疗(如IVIG)对部分症状的改善。
3. **"Paraneoplastic neurological syndromes with CRMP5/CV2 autoantibodies: A heterogeneous clinical spectrum"**
- **作者**：Titulaer MJ, et al.
- **摘要**：文章描述了CRMP5抗体相关神经综合征的多样性，包括脑脊髓炎、神经性疼痛及视神经炎，指出抗体滴度与疾病活动度的相关性，并建议长期随访以监测潜在肿瘤复发或神经功能恶化。
4. **"Antibody profiles in paraneoplastic syndromes: Insights from CRMP5 and other neural antigens"**
- **作者**：Dalmau J, et al.
- **摘要**：综述了CRMP5抗体在副肿瘤综合征中的诊断价值，强调其与其他抗神经元抗体(如抗Hu、抗Ri)的共存现象，以及其在指导肿瘤早期发现和免疫治疗策略中的作用。
以上文献涵盖CRMP5抗体的临床表现、诊断关联及治疗意义，适用于神经免疫学领域研究参考。
CRMP5 antibody, directed against collapsin response mediator protein 5 (CRMP5), is an onconeural antibody associated with paraneoplastic neurological syndromes (PNS). CRMP5. a 62-kDa cytoplasmic protein encoded by the *DPYSL5* gene, plays a role in axonal guidance, neuronal differentiation, and synaptic plasticity. First identified in the 1990s, CRMP5 antibodies are commonly detected in patients with underlying malignancies, particularly small-cell lung cancer (SCLC) and thymoma. These antibodies are part of a broader group of paraneoplastic antibodies linked to immune-mediated neurological dysfunction.
CRMP5 antibody-related syndromes often manifest as encephalomyelitis, cerebellar ataxia, optic neuritis, or peripheral neuropathy. Retinal involvement, such as cancer-associated retinopathy (CAR), is also reported. Unlike some paraneoplastic antibodies (e.g., anti-Hu), CRMP5 antibodies may co-occur with other antibodies (e.g., anti-Hu or anti-Ri), complicating clinical presentations. Diagnosis relies on antibody detection via indirect immunofluorescence or cell-based assays, often paired with cerebrospinal fluid analysis.
Treatment focuses on immunotherapy (e.g., corticosteroids, IVIG) and addressing the underlying malignancy. Prognosis varies, with early intervention improving outcomes. Research continues to clarify CRMP5's pathogenic role, though its presence remains a crucial biomarker for guiding cancer screening in PNS.
×
